<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04496024</url>
  </required_header>
  <id_info>
    <org_study_id>PI2019_843_0018</org_study_id>
    <nct_id>NCT04496024</nct_id>
  </id_info>
  <brief_title>Ofloxacin Concentration-toxicity Relationship in the Elderly</brief_title>
  <acronym>ROSCO</acronym>
  <official_title>Determination of a Trough Serum Concentration of Ofloxacin Associated to Increase in Side Effects Frequency in Elderly Treated for Bone and Joint Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to&#xD;
      sensible staphylococcus strains. However, in the elderly, inter-individual variability of the&#xD;
      pharmacokinetics may reduce the efficacy or increase toxicity. The occurrence of ofloxacin&#xD;
      side effects is likely to be increased in case of higher exposition. However, the serum&#xD;
      concentration-toxicity relationship has not yet been determined. The purpose of this project&#xD;
      is to assess the association between the residual serum concentration of ofloxacin at day 3&#xD;
      and the occurrence of at least one adverse effect attributable to ofloxacin, and determine a&#xD;
      threshold toxicity concentration if this association exists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of one adverse reaction attributable to ofloxacin in patients with bone and joint infections</measure>
    <time_frame>day 3</time_frame>
    <description>Frequency of at least one adverse reaction attributable to ofloxacin in patients with bone and joint infections</description>
  </primary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Ofloxacin</condition>
  <condition>Bone and Joint Infection</condition>
  <condition>Therapeutic Drug Monitoring</condition>
  <condition>Adverse Drug Reactions</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ofloxacin</intervention_name>
    <description>ofloxacin treatment in patients with bone and joint infections</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ofloxacin Serum concentration</intervention_name>
    <description>Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged over 65 years hospitalized at the University Hospital of Amiens for an&#xD;
             uncomplicated bone and joint infections&#xD;
&#xD;
          -  Indication for oral switch to ofloxacin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusing to participate in the study&#xD;
&#xD;
          -  Patient under guardianship or curators or deprived of public rights&#xD;
&#xD;
          -  Any liver or biliary injury&#xD;
&#xD;
          -  Any contraindications to ofloxacin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youssef BENNIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Philippe LANOIX, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youssef BENNIS, MD</last_name>
    <phone>(33)32208700</phone>
    <email>bennis.youssef@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youssef Bennis, MD</last_name>
      <phone>03 22 08 70 00</phone>
      <email>bennis.youssef@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Philippe LANOIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc SCHMIT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youssef EL SAMAD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beno√Æt BRUNSCHWEILER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ofloxacin</keyword>
  <keyword>Bone and Joint Infection</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <keyword>Adverse Drug Reactions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

